86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

18 trials found

diseases per page:

Showing 1 to 10 of 18 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03992755 (ClinicalTrials.gov)	July 18, 2019	5/6/2019	Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inh ...	A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Saf ...	Primary Pulmonary Hypertension	Drug: LIQ861 Inhaled Treprostinil	Liquidia Technologies, Inc.	Nuventra, Inc.	Active, not recruiting	18 Years	N/A	All	92	Phase 3	United States
2	EUCTR2018-003414-40-DE (EUCTR)	31/01/2019	06/11/2018	A Two Part Clinical Study to Evaluate the Effect of Different Doses and the Safety of Inhaled Trepro ...	A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Res ...	Pulmonary Arterial Hypertension (WHO Group 1) MedDRA version: 20.0;Level: LLT;Classification code 10 ...	Product Name: LIQ861 26.5 µg INN or Proposed INN: Treprostinil Sodium Other descriptive name: TREPROSTI ...	Liquidia Technologies, Inc.	NULL	Not Recruiting			Female: yes Male: yes	32	Phase 2	France;Germany
3	EUCTR2018-003414-40-FR (EUCTR)	21/01/2019	06/11/2018	A Two Part Clinical Study to Evaluate the Effect of Different Doses and the Safety of Inhaled Trepro ...	A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Res ...	Pulmonary Arterial Hypertension (WHO Group 1) MedDRA version: 20.0;Level: LLT;Classification code 10 ...	Product Name: LIQ861 25 µg INN or Proposed INN: Treprostinil Sodium Other descriptive name: TREPROSTINI ...	Liquidia Technologies, Inc.	NULL	Not Recruiting			Female: yes Male: yes	32	Phase 2	France;Germany
4	NCT03399604 (ClinicalTrials.gov)	January 2, 2018	3/1/2018	Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil	A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled ...	Primary Pulmonary Hypertension	Drug: LIQ861 Inhaled Treprostinil	Liquidia Technologies, Inc.	Nuventra, Inc.	Completed	18 Years	N/A	All	121	Phase 3	United States
5	NCT02471183 (ClinicalTrials.gov)	November 4, 2015	11/6/2015	Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinilto Oral S ...	Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transit ...	Pulmonary Arterial Hypertension	Drug: Selexipag	Actelion	NULL	Completed	18 Years	75 Years	All	30	Phase 3	United States
6	NCT01557647 (ClinicalTrials.gov)	June 2012	14/3/2012	Safety and Efficacy of Inhaled Treprostinil in Patients With PAH	Inhaled Treprostinilfor the Treatment of Pulmonary Arterial Hypertension: A Phase III, International ...	Pulmonary Arterial Hypertension	Drug: Inhaled treprostinil;Drug: Placebo	United Therapeutics	NULL	Withdrawn	18 Years	75 Years	Both	0	Phase 3	NULL
7	NCT01557660 (ClinicalTrials.gov)	June 2012	14/3/2012	Inhaled Treprostinil for PAH: Open-label Extension	Inhaled Treprostinilin Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, Inte ...	Pulmonary Arterial Hypertension	Drug: inhaled treprostinil	United Therapeutics	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 3	NULL
8	NCT01268553 (ClinicalTrials.gov)	August 2010	29/12/2010	Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication	Transition From Parenteral Prostanoids to Inhaled Treprostinil	Pulmonary Arterial Hypertension	Drug: Treprostinil	Los Angeles Biomedical Research Institute	United Therapeutics	Completed	18 Years	80 Years	All	6	Phase 4	United States
9	NCT01305252 (ClinicalTrials.gov)	July 2010	2/11/2010	A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostiniland Tadafafil) Versus Monotherapy ...	CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprost ...	Hypertension, Pulmonary	Drug: treprostinil inhalations;Drug: tadalafil	Stanford University	Northwestern University	Completed	18 Years	69 Years	All	21	Phase 4	United States
10	NCT00741819 (ClinicalTrials.gov)	September 2008	23/8/2008	Safety Evaluation of Inhaled TreprostinilAdministration Following Transition From Inhaled Ventavis i ...	An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled TreprostinilAdministrat ...	Pulmonary Arterial Hypertension	Drug: Inhaled treprostinil	United Therapeutics	NULL	Completed	18 Years	75 Years	All	73	Phase 4	United States

First Previous1 2Next Last